Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 17/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.32 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089434 | 1.00 | NOTUM (0.38) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL5802974 | 0.78 | HTT (0.36) | CYP1A2CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL10518873 | 0.78 | CA12 (0.38) | CYP1A2CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL5802975 | 0.78 | HTT (0.36) | CYP1A2CYP2C9CYP2C19HPGDHTT | |
| SCHEMBL1591369 | 0.77 | NOTUM (0.41) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL18502976 | 0.76 | NOTUM (0.38) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL18508604 | 0.76 | NOTUM (0.38) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL7550001 | 0.74 | CA12 (0.38) | CYP1A2CYP2C9MAOACYP2C19HPGD | |
| SCHEMBL7550008 | 0.74 | CA12 (0.38) | CYP1A2CYP2C9MAOACYP2C19HPGD | |
| SCHEMBL1751285 | 0.74 | CA12 (0.40) | CYP1A2CYP2C9CYP2C19EPAS1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| WO-2006064484-A1 | AZABICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | NOTUM 3054/4885CYP1A2 3987/4885CYP2C9 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.